First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.

"Declarations Ethics approval and consent to participateThe study protocol was approved by the Institutional Review Board of the Charité Medical School (EA1/238/22). Informed consent was not necessary according to state legislations (Berliner Landeskrankenhausgesetz (LKG) of September 18, 2011, § 25). All the analyses were conducted in accordance with the principles of the Declaration of Helsinki. Consent for publicationNot applicable. Competing interestsT.P. was supported by the Berlin Institute of Health (Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021, 68GX21001A), German Research Foundation (DFG, SFB 1340/2), European Union (H2020: 952172, DIGITAL:101100633) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier).P.B. is participant in the BIH Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH).All other authors declare no competing interests.We declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported. Competing interests T.P. was supported by the Berlin Institute of Health (Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021, 68GX21001A), German Research Foundation (DFG, SFB 1340/2), European Union (H2020: 952172, DIGITAL:101100633) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier). P.B. is participant in the BIH Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH). All other authors declare no competing interests. We declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported."

"Funding Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector. K.M. was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Project-ID 424957847—TRR 296. Open Access funding enabled and organized by Projekt DEAL."